Vasarya Therapeutics

Vasarya Therapeutics is a private biotechnology company developing targeted therapies for fibrotic diseases. The company is building a mechanobiology-based platform aimed at proteins and epitopes that are exposed or functional specifically in actively remodeling fibrotic tissue, with the goal of improving efficacy while avoiding the systemic toxicities seen with broader anti-fibrotic approaches. Its lead disclosed program, VSR-H5, is being advanced in preclinical studies for idiopathic pulmonary fibrosis and liver fibrosis. Vasarya appears to be closely connected to University of Virginia-originated science and has been supported by NIH SBIR/STTR funding and regional venture and university-backed investors.